The Day In Review: Troubled Trials Dominate News

March 24, 2006 – Idenix Pharma eliminated the high-dose regimen of valocitabine, a hepatitis C drug, in a Phase IIb trial; Antigenics reported that its therapeutic vaccine for kidney cancer, Oncophage, failed a Phase III trial; Encysive Pharma put off human testing of a hypertension drug after a rat displayed abnormalities; European regulatory officials recommended approval of a glaucoma drug from Allergan; the FDA told King Pharma that an additional trial will be necessary to approve a pediatric hypertension therapy; and.Lilly released data showing that Cymbalta was effective against generalized anxiety disorder. The Centient Biotech 200™ was down 9 points at 3995.65, a loss of .21%. More details...